$ Value
$0
Shares
3,408
Price
$0
Filed
Apr 1
Insider
Name
Tezel Ahmet
Title
Chief Innovation Officer
CIK
0002023439
Roles
Transaction Details
Transaction Date
2026-03-30
Code
M
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
5,343
Footnotes
Reporting person had vested restricted stock units (RSUs) settled in ordinary shares of LivaNova PLC (the Company), GBP 1.00 par value. | Shares withheld to satisfy tax liability. | Each RSU represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. | On March 30, 2025, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2026. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the First Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the First A&R 2022 Plan) and the award agreement. | On March 30, 2026, reporting person was granted RSUs subject to a three-year vesting in equal annual installments, the first vesting occurring on March 30, 2027. The RSUs are subject to forfeiture prior to vesting in accordance with the terms of the Second Amended and Restated LivaNova PLC 2022 Incentive Award Plan (the Second A&R 2022 Plan) and the award agreement. | Each performance stock unit (PSU) represents a contingent right to receive one ordinary share of the Company in accordance with the terms of the applicable Company incentive award plan identified in the footnote for such grant and the award agreement. | On March 30, 2026, reporting person was granted PSUs to vest or lapse on March 30, 2029 based on how the Company's revenue growth for the performance period 2026-2028 compares to a target determined by the Second A&R 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. | On March 30, 2026, reporting person was granted PSUs to vest or lapse on March 30, 2029 based on the Company's relative total shareholder return (rTSR) for the three-year period beginning on January 1, 2026 and ending December 31, 2028 relative to the total shareholder return of an index of companies, as determined by the Second A&R 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement. | On March 30, 2026, reporting person was granted PSUs to vest or lapse on March 30, 2029 based on how the Company's adjusted earnings per share (EPS) for the performance period 2026-2028 compares to a target determined by the Second A&R 2022 Plan Administrator. The number included in column 5 of Table II reflects the target number of PSUs eligible for vesting subject to continued service during the vesting period and the award agreement.
Filing Info
Tezel Ahmet's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-03-30 | LIVN | M | $0 |
| 2026-03-30 | LIVN | F | $73K |
| 2026-03-30 | LIVN | M | $0 |
| 2026-03-30 | LIVN | A | $0 |
| 2026-03-30 | LIVN | A | $0 |
| 2026-03-30 | LIVN | A | $0 |
| 2026-03-30 | LIVN | A | $0 |
| 2025-06-15 | LIVN | M | $0 |
| 2025-06-15 | LIVN | F | $47K |
| 2025-06-15 | LIVN | M | $0 |
Other Insiders at LIVN (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
Shvartsburg Alex
Chief Financial Officer
|
— | — | 2026-03-30 |
|
Bolton Stephanie
President, Global Epilepsy
|
— | — | 2026-03-30 |
|
Makatsaria Vladimir
Chief Executive Officer
|
— | — | 2026-03-30 |
|
Tezel Ahmet
Chief Innovation Officer
|
— | — | 2026-03-30 |
|
Poletti Franco
President, Cardiopulmonary
|
— | — | 2026-03-30 |
|
Kozmina Natalia
Chief Human Resources Officer
|
— | — | 2026-03-30 |